Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma

In hepatocellular carcinoma (HCC), blood platelets have been linked to tumor growth, epithelial-to-mesenchymal transition (EMT), extrahepatic metastasis and a limited therapeutic response to the multikinase inhibitor (MKi) sorafenib, the standard of care in advanced HCC for the last decade. Recent c...

Descripción completa

Detalles Bibliográficos
Autores principales: Streubel, Gundula, Schrepfer, Sabine, Kallus, Hannah, Parnitzke, Ulrike, Wulff, Tanja, Hermann, Frank, Borgmann, Matthias, Hamm, Svetlana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100298/
https://www.ncbi.nlm.nih.gov/pubmed/33953226
http://dx.doi.org/10.1038/s41598-021-88983-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100298/
https://www.ncbi.nlm.nih.gov/pubmed/33953226
http://dx.doi.org/10.1038/s41598-021-88983-1

Ejemplares similares